Focus on Adoptive T Cell Transfer Trials in Melanoma
Adoptive Cell Transfer (ACT) of Tumor-Infiltrating Lymphocytes (TIL) in combination with lymphodepletion has proven to be an effective treatment for metastatic melanoma patients, with an objective response rate in 50%–70% of the patients. It is based on the ex vivo expansion and activation of tumor-...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2010-01-01
|
| Series: | Clinical and Developmental Immunology |
| Online Access: | http://dx.doi.org/10.1155/2010/260267 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832552724927873024 |
|---|---|
| author | Liat Hershkovitz Jacob Schachter Avraham J. Treves Michal J. Besser |
| author_facet | Liat Hershkovitz Jacob Schachter Avraham J. Treves Michal J. Besser |
| author_sort | Liat Hershkovitz |
| collection | DOAJ |
| description | Adoptive Cell Transfer (ACT) of Tumor-Infiltrating Lymphocytes (TIL) in combination with lymphodepletion has proven to be an effective treatment for metastatic melanoma patients, with an objective response rate in 50%–70% of the patients. It is based on the ex vivo expansion and activation of tumor-specific T lymphocytes extracted from the tumor and their administration back to the patient. Various TIL-ACT trials, which differ in their TIL generation procedures and patient preconditioning, have been reported. In the latest clinical studies, genetically engineered peripheral T cells were utilized instead of TIL. Further improvement of adoptive T cell transfer depends on new investigations which seek higher TIL quality, increased durable response rates, and aim to treat more patients. Simplifying this therapy may encourage cancer centers worldwide to adopt this promising technology. This paper focuses on the latest progress regarding adoptive T cell transfer, comparing the currently available protocols and discussing their advantages, disadvantages, and implication in the future. |
| format | Article |
| id | doaj-art-8f6f17a5f1ee47fb84b3e59cb4e1dd56 |
| institution | Kabale University |
| issn | 1740-2522 1740-2530 |
| language | English |
| publishDate | 2010-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Clinical and Developmental Immunology |
| spelling | doaj-art-8f6f17a5f1ee47fb84b3e59cb4e1dd562025-02-03T05:58:03ZengWileyClinical and Developmental Immunology1740-25221740-25302010-01-01201010.1155/2010/260267260267Focus on Adoptive T Cell Transfer Trials in MelanomaLiat Hershkovitz0Jacob Schachter1Avraham J. Treves2Michal J. Besser3Ella Institute of Melanoma, Sheba Medical Center, Tel-Hashomer 52621, IsraelElla Institute of Melanoma, Sheba Medical Center, Tel-Hashomer 52621, IsraelSheba Cancer Research Center, Sheba Medical Center, Tel-Hashomer 52621, IsraelElla Institute of Melanoma, Sheba Medical Center, Tel-Hashomer 52621, IsraelAdoptive Cell Transfer (ACT) of Tumor-Infiltrating Lymphocytes (TIL) in combination with lymphodepletion has proven to be an effective treatment for metastatic melanoma patients, with an objective response rate in 50%–70% of the patients. It is based on the ex vivo expansion and activation of tumor-specific T lymphocytes extracted from the tumor and their administration back to the patient. Various TIL-ACT trials, which differ in their TIL generation procedures and patient preconditioning, have been reported. In the latest clinical studies, genetically engineered peripheral T cells were utilized instead of TIL. Further improvement of adoptive T cell transfer depends on new investigations which seek higher TIL quality, increased durable response rates, and aim to treat more patients. Simplifying this therapy may encourage cancer centers worldwide to adopt this promising technology. This paper focuses on the latest progress regarding adoptive T cell transfer, comparing the currently available protocols and discussing their advantages, disadvantages, and implication in the future.http://dx.doi.org/10.1155/2010/260267 |
| spellingShingle | Liat Hershkovitz Jacob Schachter Avraham J. Treves Michal J. Besser Focus on Adoptive T Cell Transfer Trials in Melanoma Clinical and Developmental Immunology |
| title | Focus on Adoptive T Cell Transfer Trials in Melanoma |
| title_full | Focus on Adoptive T Cell Transfer Trials in Melanoma |
| title_fullStr | Focus on Adoptive T Cell Transfer Trials in Melanoma |
| title_full_unstemmed | Focus on Adoptive T Cell Transfer Trials in Melanoma |
| title_short | Focus on Adoptive T Cell Transfer Trials in Melanoma |
| title_sort | focus on adoptive t cell transfer trials in melanoma |
| url | http://dx.doi.org/10.1155/2010/260267 |
| work_keys_str_mv | AT liathershkovitz focusonadoptivetcelltransfertrialsinmelanoma AT jacobschachter focusonadoptivetcelltransfertrialsinmelanoma AT avrahamjtreves focusonadoptivetcelltransfertrialsinmelanoma AT michaljbesser focusonadoptivetcelltransfertrialsinmelanoma |